Loading organizations...
Key people at Samho Green Investment.
Samho Green Investment is a dedicated venture capital firm specializing in investments within high and emerging technology sectors. The firm focuses on opportunities in clean technology, nanotechnology, and other advanced growth areas, particularly within the clean growth sector. As a venture capital and private equity investor, it provides crucial capital and strategic guidance to foster innovation and development in these specialized fields.
The company was established in 2007 in Seoul, South Korea. Soobong Cho serves as the Chief Executive Officer, bringing over three decades of experience in risk management, credit rating, valuation, feasibility studies, and various investment activities. The firm's inception was driven by an identified need to support the nascent clean growth sector in Korea, positioning itself as a pioneering venture capital entity in this domain.
Samho Green Investment supports small and medium-sized venture companies, deploying capital into enterprises poised for significant development in their respective markets. The firm’s overarching vision is to contribute to the growth of the clean energy and advanced technology landscape in Korea by actively participating in the expansion and merger and acquisition activities of promising companies.
Key people at Samho Green Investment.
Samho Green Investment has 3 tracked investments across 2 companies. The latest tracked deal is $47.0M Series B in PineTree Therapeutics in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 28, 2025 | PineTree Therapeutics | $47.0M Series B | — | Atinum Investment, Yohan KIM, Gauss Capital Management, Korea Investment Partners, SJ Investment Partners, Smilegate Investment, S&S Investment, Stic Ventures, SV Investment, Widwin Investment |
| Jun 8, 2022 | PineTree Therapeutics | $23.5M Series A | — | DSC Investment, Intervest, J Curve Investment, SJ Investment Partners, SK Securities |
| Mar 29, 2021 | Master Meditech | $7.1M Series A | — | Foresite Capital, Huons, INNOCENCE, King Mind Partners, Paratus Investment, Pharmbio, Springcamp |